In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine

Journal of Pharmaceutical Sciences

Volumn 99, Issue 11, 2010, Pages 4565-4575

  Hemenway, Jeffrey N ^a,b   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bioavailability; Carbamazepine; N Gly CBZ; Pharmacokinetics; Prodrug

Indexed keywords

CARBAMAZEPINE; CYCLODEXTRIN; GLYCINE; N GLYCYLCARBAMAZEPINE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

EID: 78149315029     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22171     Document Type: Article

References (40)

1. Levy RH, Mattson RH, Meldrum BS. 1995. Antiepileptic drugs. 4th edition. New York: Raven Press. p. 1120.
2. Loiseau P, Duche B, Pedespan JM. 1985. Absence epilepsies. Epilepsia 36: 1182-1186.
3. Chen X-Q, Venkatesh S. 2004. Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharm Res 21: 1758-1761.
4. Brewster ME, Anderson WR, Estes KS, Bodor N. 1991. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. J Pharm Sci 80: 380-383.
5. Rall TW, Schleifer LS. 1985. Drugs effective in the therapy of the epilepsies. In: Goodman MBG, editor. The pharmacological basis of therapeutics. 7th edition. New York: Macmillan. pp. 446-472.
6. Morselli PL, Monaco F, Gerna M, Recchia M, Riccio A. 1975. Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients. Epilepsia 16: 759-764.
7. McMahon LE, Timmins P, Williams AC, York P. 1996. Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci 85: 1064-1069.
8. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193: 137-146.
9. Kaneniwa N, Ichikawa J, Yamaguchi T, Hayashi K, Watari N, Sumi M. 1987. Dissolution behavior of carbamazepine polymorphs. Yakugaku Zasshi 107: 808-813.
10. Lang M, Kampf Jeff W, Matzger Adam J. 2002. Form IV of carbamazepine. J Pharm Sci 91: 1186-1190.
11. Laine E, Tuominen V, Ilvessalo P, Kahela P. 1984. Formation of dihydrate from carbamazepine anhydrate in aqueous conditions. Int J Pharm 20: 307-314.
12. Kahela P, Aaltonen R, Lewing E, Anttila M, Kristoffersson E. 1983. Pharmacokinetics and dissolution of two crystalline forms of carbamazepine. Int J Pharm 14: 103-112.
13. Lake OA, Olling M, Barends DM. 1999. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur J Pharm Biopharm 48: 13-19.
14. Yalkowsky SH, Krzyzaniak JF, Ward GH. 1998. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 87: 787-795.
15. Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci 91: 2283-2300.
16. Johnson JLH, He Y, Yalkowsky SH. 2003. Prediction of precipitation-induced phlebitis: A statistical validation of an in vitro model. J Pharm Sci 92: 1574-1581.
17. Yalkowsky SH, Valvani SC, Johnson BW. 1983. In vitro method for detecting precipitation of parenteral formulations after injection. J Pharm Sci 72: 1014-1017.
18. Oshida S, Degawa K, Takahashi Y, Akaishi S. 1979. Physico-chemical properties and local toxic effects of injectables. Tohoku J Exp Med 127: 301-316.
19. Yalkowsky SH, Valvani SC. 1977. Precipitation of solubilized drugs due to injection or dilution. Drug Intell Clin Pharm 11: 417-419.
20. Serembe M. 1960. Hydrolysis of water-soluble esters of chloramphenicol and their antibacterial activity in vitro and in vivo. Minerva Med 51: 517-521.
21. Trivellato E, Malesani L, Concilio C. 1958. Some new esters of chloramphenicol. IV. Pharmacological research on chloramphenicol glycinate. Farmaco Prat 13: 399-405.
22. Bundgaard H, Larsen C, Thorbek P. 1984. Prodrugs as drug delivery systems. XXVI. Preparation and enzymic hydrolysis of various water-soluble amino acid esters of metronidazole. Int J Pharm 18: 67-77.
23. Stella VJ, Kennedy PE. 1987. Water-soluble rapamycin prodrugs. Us Patent 4650803. ed. (University of Kansas, USA). p. 6.
24. Pop E, Soti F, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, Nadler V, Biegon A. 1996. Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. Pharm Res 13: 469-475.
25. Stevens MFG, Poole TD, Westwell AD, Hutchinson IP, Chua M-S. 2001. Preparation of substituted 2-phenylbenzothiazoles as antitumor agents. PCT Int. Appl. 2001014354. ed. Cancer Research Campaign Technology Limited, UK. p. 58.
26. Hirai K, Koike H, Ishiba T, Ueda S, Makino I, Yamada H, Ichihashi T, Mizushima Y, Ishikawa M, Ishihara Y, Hara Y, Hirose H, Shima N, Doteuchi M. 1991. Amino acid amides of 2-[(2-aminobenzyl)sulfinyl]benzimidazole as acid-stable prodrugs of potential inhibitors of H+/K+ ATPase. Eur J Med Chem 26: 143-158.
27. Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD, Stevens MFG. 2002. Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 45: 744-747.
28. Pochopin NL, Charman WN, Stella VJ. 1995. Amino acid derivatives of dapsone as water-soluble prodrugs. Int J Pharm 121: 157-167.
29. Pochopin NL, Charman WN, Stella VJ. 1994. Kinetics of rearrangement and hydrolysis of amino acid derivatives of prazosin. Int J Pharm 105: 169-176.
30. Pochopin NL, Charman WN, Stella VJ. 1994. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab Dispos 22: 770-775.
31. Hemenway JN, Jarho P, Henri JT, Nair SK, VanderVelde D, Georg GI, Stella VJ. Preparation and physicochemical characterization of a novel water-soluble prodrug of carbamazepine. J Pharm Sci 99: 1810-1825.
32. Sawada Y, Harashima H, Hanano M, Sugiyama Y, Iga T. 1985. Prediction of the plasma concentration time courses of various drugs in humans based on data from rats. J Pharmacobiodyn 8: 757-766.
33. Boxenbaum H. 1980. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8: 165-176.
34. Grasela DM, Rocci ML, Jr. 1984. Liquid chromatographic microassay for carbamazepine and its 10, 11-epoxide in plasma. J Pharm Sci 73: 1874-1875.
35. Yesilaltay AK, Ersoy O, Omurtag GZ, Yurdun T. 1998. Effects of carbamazepine on hepatic glutathione level in rats and determination of carbamazepine and its epoxide metabolite in plasma by HPLC. Drug Metabol Drug Interact 14: 251-258.
36. Yamashita S, Furuno K, Moriyama M, Kawasaki H, Gomita Y. 1997. Effects of various antiepileptic drugs on plasma levels of lamotrigine, a novel antiepileptic, in rats. Pharmacology 54: 319-327.
37. Remmel RP, Sinz MW, Cloyd JC. 1990. Dose-dependent pharmacokinetics of carbamazepine in rats: Determination of the formation clearance of carbamazepine-10, 11-epoxide. Pharm Res 7: 513-517.
38. Peters S, Hampsch J, Cregor MCSGGCK. 2000. Culex ABS Part I: Introduction to automated blood sampling. Curr Sep 18: 139-145.
39. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
40. Gerardin A, Dubois JP, Moppert J, Geller L. 1990. Absolute bioavailability of carbamazepine after oral administration of a 2% syrup. Epilepsia 31: 334-338.